Your browser doesn't support javascript.
loading
Chemically generated IgG2 bispecific antibodies through disulfide bridging.
Patterson, James T; Gros, Edwige; Zhou, Heyue; Atassi, Ghazi; Kerwin, Lisa; Carmody, Lisa; Zhu, Tong; Jones, Bryan; Fu, Yanwen; Kaufmann, Gunnar F.
  • Patterson JT; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA. Electronic address: jpatterson@sorrentotherapeutics.com.
  • Gros E; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Zhou H; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Atassi G; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Kerwin L; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Carmody L; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Zhu T; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Jones B; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Fu Y; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.
  • Kaufmann GF; Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA. Electronic address: gkaufmann@sorrentotherapeutics.com.
Bioorg Med Chem Lett ; 27(16): 3647-3652, 2017 08 15.
Article en En | MEDLINE | ID: mdl-28720505
ABSTRACT
Bispecific antibodies (BsAbs) are designed to engage two antigens simultaneously, thus, effectively expanding the ability of antibody-based therapeutics to target multiple pathways within the same cell, engage two separate soluble antigens, bind the same antigen with distinct paratopes, or crosslink two different cell types. Many recombinant BsAb formats have emerged, however, expression and purification of such constructs can often be challenging. To this end, we have developed a chemical strategy for generating BsAbs using native IgG2 architecture. Full-length antibodies can be conjugated via disulfide bridging with linkers bearing orthogonal groups to produce BsAbs. We report that an αHER2/EGFR BsAb was successfully generated by this approach and retained the ability to bind both antigens with no significant loss of potency.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Anticuerpos Biespecíficos / Disulfuros Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Anticuerpos Biespecíficos / Disulfuros Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article